Kymera Therapeutics, Inc. (KYMR)
Nasdaq · Healthcare · Biotechnology
$109.85+2.29%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.0B
- 52-week range
- $55.26 – $130.05
- 52-week change
- +86.60%
- EPS (trailing)
- −$3.25
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $39.2M (−16.70%)
- Net income
- $311M
- Operating margin
- −891.1%
- Diluted EPS
- −$3.69
- Free cash flow
- −$234M
From the company’s annual report on SEC EDGAR.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Headquarters: Watertown, United States · 273 employees · kymeratx.com